Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies

The growing landscape of tubulin acetylation: lysine 40 and many more

(2016) K. Sadoul et al.   BIOCHEMICAL JOURNAL

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

(2016) L. Zhou et al.   BLOOD

The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies

(2016) Madeleine Duvic et al.   CANCER TREATMENT REVIEWS

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

(2015) Enrica Marchi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma

(2015) K. M. Zullo et al.   CLINICAL CANCER RESEARCH

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia

(2015) Maria Teresa Voso et al.   CURRENT OPINION IN ONCOLOGY

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

(2014) M. Bots et al.   BLOOD

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

(2014) Teresa Palomero et al.   NATURE GENETICS

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation

(2013) H W Auner et al.   BONE MARROW TRANSPLANTATION

Differential expression of aurora-A kinase in T-cell lymphomas

(2013) Rashmi Kanagal-Shamanna et al.   MODERN PATHOLOGY

Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor-Induced DNA Damage and Apoptosis

(2013) L. A. Petruccelli et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation

(2012) M.S.F. Zawawi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Mutation of calcineurin subunit B M118 influences the activities of NF-AT and p53, but not calcineurin expression level

(2011) Jinbo Cheng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

NFATc1 affects mouse splenic B cell function by controlling the calcineurin–NFAT signaling network

(2011) Sankar Bhattacharyya et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

(2010) A. Mandawat et al.   BLOOD

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates  4 integrins

(2008) Y. Imai et al.   BLOOD

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE